GLP-1s for PCOS: what the guideline allows, what the trials show, and what it costs

Q: Is Ozempic or Wegovy approved for PCOS?

No. No GLP-1 is FDA approved for PCOS. Wegovy is approved for weight reduction in adults with obesity, or with overweight plus a weight-related condition, among other uses. Doctors can prescribe it to someone with PCOS who meets that weight indication, or off-label, the same way metformin has long been used for PCOS without an FDA approval for it.

Q: Does a GLP-1 help PCOS symptoms like irregular periods and hair growth?

Possibly, but the evidence is weak. A 2023 meta-analysis of 11 trials found more regular periods, but results varied widely between trials, and a 2026 review of 11 trials judged the evidence insufficient to conclude anything on periods or excess hair. The clearest benefit is weight loss, and the Office on Women's Health says losing 10% of body weight can help make periods more regular.

Q: Can a GLP-1 help me get pregnant with PCOS?

One 2023 meta-analysis found a higher natural pregnancy rate (risk ratio 1.72), and small 2026 studies of tirzepatide and semaglutide with metformin reported pregnancies. But the 2023 International PCOS Guideline recommends using weight medicines for fertility only in research settings, and the Wegovy label says to stop at least 2 months before a planned pregnancy.

Q: Is tirzepatide (Zepbound, Mounjaro) better than semaglutide for PCOS?

Nobody has compared them in PCOS. The first randomized tirzepatide trial in PCOS gave 60 women metformin with or without tirzepatide 5 mg for 16 weeks: 10.4 kg lost with the combination versus 1.7 kg on metformin alone. The 2023 guideline names liraglutide and semaglutide, not tirzepatide.

Q: Can I take a GLP-1 with metformin or birth control pills for PCOS?

Both combinations were used in the PCOS trials, and your prescriber decides. If the GLP-1 is tirzepatide and you take the pill, the Zepbound label says to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.

Q: How much does a GLP-1 for PCOS cost without insurance?

The same as for anyone else. On our board today the cheapest cash program is $69 a month, compounded tirzepatide starts at $85, and the middle program is $158. A licensed clinician must prescribe it, and compounded versions are not FDA approved.

No GLP-1 is FDA approved for PCOS. The 2023 International PCOS Guideline says liraglutide and semaglutide could be considered for higher weight in adults with PCOS, alongside lifestyle changes. The trials agree on weight: a 2026 review of 11 randomized trials showed a modest BMI drop. Effects on periods, hair growth and hormones are less certain, and the guideline keeps fertility use to research settings. Stop semaglutide 2 months before trying to conceive.

Julian CaraulaniFounder, PriceTracker GLP-1Last checked October 2026

9 min read · published October 2026

Key takeaways

1Not FDA approved for PCOS: the Wegovy and Zepbound labels cover weight, heart, sleep apnea and liver uses, not PCOS. Metformin, the older standby, is not FDA approved for PCOS either.
2The 2023 International PCOS Guideline: liraglutide and semaglutide “could be considered” with lifestyle changes to manage higher weight in adults with PCOS, with contraception when pregnancy is possible.
3Weight is the solid finding: a 2026 review of 11 randomized trials showed a BMI drop of 1.38 kg/m2 (low certainty). Evidence on periods, hair growth and hormones was too thin to conclude.
4Fertility: one 2023 meta-analysis reported higher natural pregnancy rates, but the guideline says to use these drugs for fertility only in research. Wegovy says stop at least 2 months before a planned pregnancy.
5Tirzepatide: the first randomized PCOS trial (60 women, 16 weeks) reported 10.4 kg lost with metformin versus 1.7 kg on metformin alone.

No GLP-1 is FDA approved to treat PCOS, but the 2023 International PCOS Guideline says liraglutide and semaglutide "could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS".¹ The trials agree that they lower weight. Whether they also fix irregular periods, excess hair or high androgens is far less certain: a 2026 review of 11 randomized trials judged the evidence "insufficient to draw conclusion" on hirsutism and menstrual regularity.²

So a GLP-1 for PCOS is, in practice, a weight medicine prescribed to someone who has PCOS. If your weight meets the label, it is on-label for that reason; the PCOS symptoms are the hoped-for side benefit. Below is what the guideline allows, what the studies showed, strongest first, the pregnancy rules that matter more in PCOS than almost anywhere else, and what it costs.

Is any GLP-1 approved for PCOS?

No. Read the indications on the two labels most people ask about and PCOS is not among them:

Medicine	What the label says it is for	PCOS listed?
Wegovy (semaglutide)	Weight reduction in adults with obesity, or with overweight plus "at least one weight-related comorbid condition"; also heart risk reduction and MASH liver disease³	No
Zepbound (tirzepatide)	Weight reduction in adults with obesity, or with overweight plus "at least one weight-related comorbid condition"; also obstructive sleep apnea with obesity⁵	No
Metformin (for comparison)	Type 2 diabetes; the US Office on Women's Health says it "is not approved by the FDA to treat PCOS symptoms"⁷	No

That puts GLP-1s in the same place as metformin, which doctors have prescribed for PCOS for years without a PCOS label. Compounded semaglutide and tirzepatide have no FDA label at all. Whether your plan pays depends on the indication your prescriber writes and your plan's own rules, so ask the plan, not the pharmacy.

What the international PCOS guideline says

On GLP-1s, the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS says:

Guideline point	Exact wording
4.5.1 Weight	Liraglutide, semaglutide and orlistat "could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines"¹
4.5.2 Contraception	Prescribers "should ensure concurrent effective contraception when pregnancy is possible for women who take GLP-1 receptor agonists, as pregnancy safety data are lacking"¹
4.5.3 Side effects	"Gradual dose escalation for GLP-1 receptor agonists is recommended to reduce gastrointestinal adverse effects"¹
4.5.4 Long-term use	The decision should weigh "the potential need for long-term use in weight management, given the high risk for weight regain after discontinuation and the lack of long-term safety data"¹
5.9.1 Fertility	"We recommend using anti-obesity agents in PCOS for reproductive outcomes only in research settings to establish the efficacy and safety."¹¹

Two things stand out. The recommendation is for weight, not for PCOS as such, and it applies "as per general population guidelines", so the same weight thresholds apply as for anyone else. And the guideline is explicit that using these drugs to get pregnant belongs in a trial, not a routine prescription. Tirzepatide is not named in it.

What the trials show, strongest evidence first

Study	What it pooled	Result	The catch
Forslund 2026, Eur J Endocrinol	11 randomized trials, GLP-1 against placebo, lifestyle, the pill, anti-androgens or metformin²	BMI down 1.38 kg/m2 more than control; no difference in LDL cholesterol or triglycerides²	"Low certainty"; too little evidence on glucose, insulin, hair growth and periods; no study looked at quality of life or mental health²
Goldberg 2024, Obes Rev (the guideline's own review)	11 trials of weight medicines in PCOS, 996 participants⁴	"Liraglutide, semaglutide and orlistat appeared superior to placebo" for body measurements⁴	"Published data examining the effects of anti-obesity agents in women with PCOS are very limited"⁴
Austregésilo 2024, J Diabetes Complications	4 randomized trials against placebo, 176 participants⁶	Waist down 5.16 cm and BMI down 2.42 versus placebo, plus lower triglycerides and total testosterone⁶	Small; no difference in insulin resistance (HOMA-IR); 49 of 112 with side-effect data had mild effects such as nausea⁶
Zhou 2023, BMC Endocr Disord	11 randomized trials, 840 patients⁸	Natural pregnancy rate higher (risk ratio 1.72) and periods more regular⁸	No difference in total or IVF pregnancy rate; the period result varied hugely between trials (I2 95.6%)⁸

The reviews disagree on periods, and the reason is in the table: they pooled different sets of small trials, mostly of older drugs. In the placebo review, 58% of participants took liraglutide and 13% semaglutide.⁶ The one thing every review agrees on is weight.

Tirzepatide and semaglutide: the first PCOS trials

The newer, stronger drugs have only started to be tested in PCOS specifically.

Tirzepatide (the molecule in Zepbound and Mounjaro). A 2026 randomized trial gave 60 women with PCOS and overweight either metformin alone or metformin plus tirzepatide 5 mg weekly for 16 weeks. Weight fell by 10.4 kg with the combination and 1.7 kg on metformin alone, and "menstrual cycle recovery and total pregnancy rate were higher" in the combination group.¹⁰ It was open-label, in one country, and used a low dose for four months.
Semaglutide (the molecule in Ozempic and Wegovy). A 2026 pilot study followed 20 women with PCOS, obesity and prediabetes on metformin plus semaglutide 0.25 to 0.5 mg weekly for 6 months, and "60 % of the patients treated" became pregnant.¹² There was no comparison group, so it cannot say how many would have conceived anyway.

Neither study changes the guideline's position on fertility. They are reasons to watch for larger trials, not proof.

Why weight loss matters so much in PCOS

PCOS is common: the World Health Organization says it "affects an estimated 10–13% of reproductive-aged women" and that up to 70% of those affected do not know they have it.⁹ The US Office on Women's Health says losing weight "may help to lower your blood glucose levels, improve the way your body uses insulin, and help your hormones reach normal levels", and puts the target plainly: "Even a 10% loss in body weight (for example, a 150-pound woman losing 15 pounds) can help make your menstrual cycle more regular and improve your chances of getting pregnant."⁷

A GLP-1 is one way to get there. It does not replace the other PCOS treatments: WHO notes that the combined pill "can help regulate the menstrual cycle and may reduce acne or excess facial and body hair".⁹ If you take the pill alongside a GLP-1, the next section matters.

Pregnancy, fertility and the pill

The Office on Women's Health calls PCOS "one of the most common causes of infertility in women", and losing weight can improve the chances of pregnancy.⁷ That is good news if you want to conceive and a risk if you do not. Three label and guideline rules apply:

Situation	What the source says
On any GLP-1 and pregnancy is possible	The guideline says prescribers "should ensure concurrent effective contraception", because "pregnancy safety data are lacking"¹
On the pill and starting tirzepatide	Zepbound's label says to "switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation" and for 4 weeks after each dose increase⁵
Planning a pregnancy on semaglutide	Wegovy's label says to stop "at least 2 months before they plan to become pregnant"³
Pregnant on tirzepatide	Zepbound's label says "weight loss is not recommended during pregnancy" and to stop "when a pregnancy is recognized"⁵

Our GLP-1 and birth control guide works out the backup windows dose by dose and covers the patch, ring, implant and IUD, which no GLP-1 affects.

Questions to ask before you start

Am I being prescribed this for weight (on-label) or for PCOS symptoms (off-label), and does that change what my plan pays?³⁵
Should I stay on metformin or the pill alongside it?⁷⁹
If I am on the pill, which molecule am I getting, and do I need backup after each dose step?⁵
How slowly will my dose go up to limit nausea?¹
If I want to get pregnant in the next year, when do I stop, and what happens to my weight after?¹³

The last question matters: the guideline flags "the high risk for weight regain after discontinuation".¹ Our guide to stopping a GLP-1 has the trial numbers on what happens next. A program that cannot answer the first three is selling a medicine, not care; the telehealth programs guide sets out what a monthly price usually covers.

What it costs

PCOS does not change the price. On our board today the cheapest cash GLP-1 program is $69 a month, compounded semaglutide starts at $69, compounded tirzepatide at $85, and the middle program is $158. A licensed clinician decides whether you qualify, and compounded versions are not FDA approved.

For one molecule, the ranked lists are at cheapest semaglutide and cheapest tirzepatide, each checked against the sellers' own pages.

Sources12

Teede HJ et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023 (full text on PMC), section 4.5 Anti-obesity pharmacological agents read October 2026“Anti-obesity medications, including liraglutide, semaglutide, and both glucagon-like peptide-1 (GLP-1) receptor agonists and orlistat, could be considered, in addition to active lifestyle intervention, for the management of higher weight in adults with PCOS as per general population guidelines. ... Healthcare professionals should ensure concurrent effective contraception when pregnancy is possible for women who take GLP-1 receptor agonists, as pregnancy safety data are lacking. ... Gradual dose escalation for GLP-1 receptor agonists is recommended to reduce gastrointestinal adverse effects. ... Shared decision-making, when discussing GLP-1 receptor agonist use with women with PCOS, needs to consider side effects and the potential need for long-term use in weight management, given the high risk for weight regain after discontinuation and the lack of long-term safety data.” ↩
Forslund M et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2026 (11 RCTs; authors declare no conflicts) read October 2026“A total of 9654 studies were identified, 365 read in full text and 11 RCTs were included. GLP1-RAs as an add-on showed a reduction in BMI compared to the control group, mean difference (95% CI), -1.38 (-2.39 to -0.38) kg/m2 (low certainty). For LDL cholesterol and triglycerides, no difference was noted between the groups (low certainty), whereas evidence was insufficient to draw conclusion regarding glucose, insulin, hirsutism, and menstrual regularity. No studies were identified assessing quality of life, mental health, or cost-effectiveness outcomes.” ↩
Wegovy (semaglutide) prescribing information (DailyMed, revised 6/2026), highlights: indications, and section 8.3 Females and Males of Reproductive Potential read October 2026“to reduce excess body weight and maintain weight reduction long term in: o adults and pediatric patients aged 12 years and older with obesity. ( 1 ) o adults with overweight in the presence of at least one weight-related comorbid condition. ... Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide” ↩
Goldberg A et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev 2024 read October 2026“Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included. On descriptive analyses, most agents improved anthropometric outcomes; liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes. ... Published data examining the effects of anti-obesity agents in women with PCOS are very limited.” ↩
Zepbound (tirzepatide) prescribing information (DailyMed, revised 8/2026), highlights: indications, section 7.2 Oral Medications and section 8.1 Pregnancy read October 2026“to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. ... Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. ... Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue ZEPBOUND when a pregnancy is recognized” ↩
Austregésilo de Athayde De Hollanda Morais B et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials. J Diabetes Complications 2024 (GLP-1 versus placebo, 4 RCTs) read October 2026“We included 176 participants from four RCTs. Semaglutide and Liraglutide were used in 23 (13 %) and 103 (58 %) participants, respectively. GLP1-RAs use was associated with a significant reduction in waist circumference (MD: -5.16 cm; 95 % CI: -6.11 to -4.21; ... body mass index (BMI) (MD: -2.42; ... There was no significant difference in total cholesterol ... and HOMA-IR ... levels. Adverse events information was available for 112 patients, where 49 had light side effects such as nausea and abdominal pain.” ↩
Office on Women's Health, US Department of Health and Human Services: Polycystic ovary syndrome read October 2026“In fact, PCOS is one of the most common causes of infertility in women. ... Losing weight may help to lower your blood glucose levels, improve the way your body uses insulin, and help your hormones reach normal levels. Even a 10% loss in body weight (for example, a 150-pound woman losing 15 pounds) can help make your menstrual cycle more regular and improve your chances of getting pregnant. ... Metformin is often used to treat type 2 diabetes and may help some women with PCOS symptoms. It is not approved by the FDA to treat PCOS symptoms.” ↩
Zhou L et al. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr Disord 2023 (11 RCTs, 840 patients) read October 2026“GLP1RAs usage was associated with an improvement in natural pregnancy rate (RR: 1.72, 95% CI 1.22 to 2.43, P = 0.002, I2 = 0%) and menstrual regularity (SMD: 1.72, 95% CI 0.60 to 2.85, P < 0.001, I2 = 95.6%). There were no statistically significant differences in total pregnancy rate, IVF pregnancy rate between two groups” ↩
World Health Organization fact sheet: Polycystic ovary syndrome read October 2026“PCOS affects an estimated 10 ... 13% of reproductive-aged women. It is estimated that up 70% of women with PCOS worldwide do not know they have this condition. ... There is no cure for PCOS, but treatments can improve quality of life ... Combined oral contraceptive pills can help regulate the menstrual cycle and may reduce acne or excess facial and body hair.” ↩
Yang Z et al. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. Diabetes Obes Metab 2026 (60 women; authors declare no conflicts) read October 2026“Sixty overweight/obese women with PCOS were randomised to the MET group (1000 mg twice daily [BID]) or the COM group (MET: 1000 mg BID, tirzepatide: 5 mg once weekly [QW]) for 16 weeks. ... After 16 weeks of treatment, compared with the MET group, the COM group resulted in greater reductions in weight (-1.7 ± 2.5 kg vs. -10.4 ± 3.5 kg; p < 0.001) ... Menstrual cycle recovery and total pregnancy rate were higher in the COM group than in the MET group” ↩
Teede HJ et al. 2023 International PCOS Guideline recommendations (JCEM 2023, full text on PMC), section 5.9 Anti-obesity pharmacological agents (infertility) read October 2026“We recommend using anti-obesity agents in PCOS for reproductive outcomes only in research settings to establish the efficacy and safety.” ↩
Bolek T et al. Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: a pilot prospective study. Clin Nutr ESPEN 2026 (20 patients, no control group) read October 2026“We prospectively enrolled 20 consecutive PCOS patients with obesity and prediabetes, (mean age 32 years) with BMI 34.8 ± 4.3 kg/m2, on combination therapy with metformin 1000 mg daily and subcutaneous semaglutide 0.25-0.5 mg weekly. Patients were followed up for 6 months. ... Within the follow-up period, a significant improvement in fertility was observed, with 60 % of the patients treated achieving pregnancy.” ↩

Common questions

Is Ozempic or Wegovy approved for PCOS?

No. No GLP-1 is FDA approved for PCOS. Wegovy is approved for weight reduction in adults with obesity, or with overweight plus a weight-related condition, among other uses. Doctors can prescribe it to someone with PCOS who meets that weight indication, or off-label, the same way metformin has long been used for PCOS without an FDA approval for it.

Does a GLP-1 help PCOS symptoms like irregular periods and hair growth?